Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRF5 biomarker characterization study in systemic lupus erythematosus
NL-OMON58313Phase 0Recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Mar 2026
- Countries
- 1
01
Overview
Phase 0, open-label trial in systemic lupus erythematosus (SLE) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: IRF5-driven biomarkers in peripheral blood by transcriptomics and IRF5-driven biomarkers with and without TL8-506 and IMPs. Started Mar 2026; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON58313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58313.